No abstract available
Publication types
-
Evaluation Study
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antibodies, Monoclonal, Humanized / administration & dosage*
-
Antibodies, Monoclonal, Humanized / adverse effects*
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bevacizumab
-
Camptothecin / administration & dosage
-
Camptothecin / adverse effects
-
Camptothecin / analogs & derivatives
-
Camptothecin / therapeutic use
-
Carcinoma / diagnosis
-
Carcinoma / drug therapy*
-
Carcinoma / genetics
-
Carcinoma / mortality
-
Colorectal Neoplasms / diagnosis
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / genetics
-
Colorectal Neoplasms / mortality
-
DNA-Binding Proteins / genetics*
-
Enhancer of Zeste Homolog 2 Protein
-
Fluorouracil / administration & dosage
-
Fluorouracil / adverse effects
-
Fluorouracil / therapeutic use
-
Genotype
-
Humans
-
Leucovorin / administration & dosage
-
Leucovorin / adverse effects
-
Leucovorin / therapeutic use
-
Middle Aged
-
Polycomb Repressive Complex 2
-
Polymorphism, Single Nucleotide* / physiology
-
Prognosis
-
Risk Assessment
-
Survival Analysis
-
Transcription Factors / genetics*
Substances
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
DNA-Binding Proteins
-
Transcription Factors
-
Bevacizumab
-
EZH2 protein, human
-
Enhancer of Zeste Homolog 2 Protein
-
Polycomb Repressive Complex 2
-
Leucovorin
-
Fluorouracil
-
Camptothecin